Lubomirov R - Search Results

1

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A. Varona JF, et al. Among authors: lubomirov r. Life Sci Alliance. 2022 Jan 10;5(4):e202101200. doi: 10.26508/lsa.202101200. Print 2022 Apr. Life Sci Alliance. 2022. PMID: 35012962 Free PMC article. Clinical Trial.

2

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of ¹⁴C-plitidepsin.

van Andel L, Rosing H, Tibben MM, Lucas L, Lubomirov R, Avilés P, Francesch A, Fudio S, Gebretensae A, Hillebrand MJX, Schellens JHM, Beijnen JH. van Andel L, et al. Among authors: lubomirov r. Cancer Chemother Pharmacol. 2018 Sep;82(3):441-455. doi: 10.1007/s00280-018-3637-1. Epub 2018 Jul 4. Cancer Chemother Pharmacol. 2018. PMID: 29974200

3

Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.

Fernandez-Teruel C, Gonzalez I, Trocóniz IF, Lubomirov R, Soto A, Fudio S. Fernandez-Teruel C, et al. Among authors: lubomirov r. Clin Pharmacokinet. 2019 Mar;58(3):363-374. doi: 10.1007/s40262-018-0701-2. Clin Pharmacokinet. 2019. PMID: 30090974 Clinical Trial.

4

Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.

Fernández-Teruel C, Lubomirov R, Fudio S. Fernández-Teruel C, et al. Among authors: lubomirov r. J Clin Pharmacol. 2021 Sep;61(9):1206-1219. doi: 10.1002/jcph.1886. Epub 2021 Jun 9. J Clin Pharmacol. 2021. PMID: 33914350 Clinical Trial.

5

Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.

Fernández-Teruel C, Fudio S, Lubomirov R. Fernández-Teruel C, et al. Among authors: lubomirov r. Cancer Chemother Pharmacol. 2022 May;89(5):585-594. doi: 10.1007/s00280-021-04366-3. Epub 2021 Nov 5. Cancer Chemother Pharmacol. 2022. PMID: 34739582 Free PMC article.

6

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS.

King N, Garcia-Martinez S, Alcaraz E, Grisalena A, Lubomirov R, Altares R, Fernandez-Teruel C, Francesch AM, Avilés PM, Fudio S. King N, et al. Among authors: lubomirov r. PLoS One. 2023 Mar 30;18(3):e0283783. doi: 10.1371/journal.pone.0283783. eCollection 2023. PLoS One. 2023. PMID: 36996147 Free PMC article.

7

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.

Fudio S, Pérez-Ramos L, Asín-Prieto E, Zeaiter A, Lubomirov R. Fudio S, et al. Among authors: lubomirov r. Front Oncol. 2023 Jun 15;13:1152371. doi: 10.3389/fonc.2023.1152371. eCollection 2023. Front Oncol. 2023. PMID: 37397388 Free PMC article.

8

Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.

Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Martínez S, Iglesias JL, Calafati RO, Pérez-Ramos L, Montilla L, Zeaiter A, Lubomirov R. Moreno I, et al. Among authors: lubomirov r. Mar Drugs. 2024 Apr 16;22(4):178. doi: 10.3390/md22040178. Mar Drugs. 2024. PMID: 38667795 Free PMC article. Clinical Trial.

9

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.

van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, Nan-Offeringa L, Schellens JHM, Beijnen JH. van Andel L, et al. Among authors: lubomirov r. J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1. J Pharm Biomed Anal. 2018. PMID: 29883879

10

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.

Aviles P, Altares R, van Andel L, Lubomirov R, Fudio S, Rosing H, Márquez Del Pino FM, Tibben MM, Benedit G, Nan-Offeringa L, Luepke Estefan XE, Francesch A, Zeaiter A, Cuevas C, Schellens JHM, Beijnen JH. Aviles P, et al. Among authors: lubomirov r. Drug Metab Dispos. 2022 Apr;50(4):327-340. doi: 10.1124/dmd.121.000668. Epub 2022 Jan 18. Drug Metab Dispos. 2022. PMID: 35042701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters